Antiarrhythmic Drug, Cibenzoline, can Directly Improve the Left Ventricular Diastolic Function in Patients With Hypertrophic Cardiomyopathy

• Hamada Mareomi

  The Second Department of Internal Medicine, Ehime University School of Medicine

• Shigematsu Yuji

  The Second Department of Internal Medicine, Ehime University School of Medicine

• Hara Yuji

  The Second Department of Internal Medicine, Ehime University School of Medicine

• Suzuki Makoto

  The Second Department of Internal Medicine, Ehime University School of Medicine

• Ohtsuka Tomoaki

  The Second Department of Internal Medicine, Ehime University School of Medicine

• Hiasa Go

  The Second Department of Internal Medicine, Ehime University School of Medicine

• Ogimoto Akiyoshi

  The Second Department of Internal Medicine, Ehime University School of Medicine

• Saeki Hideyuki

  The Second Department of Internal Medicine, Ehime University School of Medicine

• Suzuki Jun

  The Second Department of Internal Medicine, Ehime University School of Medicine

• Hiwada Kunio

  The Second Department of Internal Medicine, Ehime University School of Medicine

抄録

The effect of cibenzoline on left ventricular diastolic function was investigated in patients with hypertrophic cardiomyopathy (HCM). Before and 2 h after an oral administration of 200 mg of cibenzoline, echocardiographic, apexcardiographic and gated radionuclide angiographic studies were performed in 12 patients with hypertrophic obstructive cardiomyopathy (HOCM) and 7 with hypertrophic nonobstructive cardiomyopathy (HNCM). After administration of cibenzoline, the left ventricular pressure gradient decreased from 96±33 mmHg to 29±22 mmHg (<0.0001). Fractional shortening decreased from 53.3±7.5 to 45.4±6.2% (p=0.0008) in patients with HOCM and from 49.9±8.7 to 40.9±7.5% (p=0.0039) in patients with HNCM. On the other hand, E-wave velocity increased and A-wave velocity decreased in both groups. The time between the second heart sound and O point was shortened from 253±53 to 176±21 ms (p<0.0001) in patients with HOCM and from 245±54 to 185±44 ms (p=0.0050) in patients with HNCM. The time to peak filling rate was shortened from 248±79 to 190±40 ms (p=0.0072) in patients with HOCM and from 218±33 to 163±26 ms (p=0.0052) in patients with HNCM. These results indicate that in patients with HCM, cibenzoline suppresses left ventricular systolic function, but can markedly improve left ventricular diastolic dysfunction through its direct action. (Jpn Circ J 2001; 65: 531 - 538)

収録刊行物

• JAPANESE CIRCULATION JOURNAL

  JAPANESE CIRCULATION JOURNAL 65 (6), 531-538, 2001

  社団法人 日本循環器学会

キーワード

• Calcium channels
• Cibenzoline
• Hypertrophic cardiomyopathy
• Left ventricular diastolic function
• Left ventricular systolic function

詳細情報

• CRID: 1390282681411020672
• NII論文ID: 130004427880
• NII論文ID: 110002625713
• NII書誌ID: AA00690731
• DOI: 10.1253/jcj.65.531
• COI: 1:CAS:528:DC%2BD3MXks1KrtrY%3D
• ISSN: 13474839
• ISSN: 00471828
• ISSN: http://id.crossref.org/issn/00471828
• ISSN: http://id.crossref.org/issn/13469843
• PubMed: 11407736
• Web Site: http://www.jstage.jst.go.jp/article/jcj/65/6/65_6_531/_pdf
• Web Site: https://search.jamas.or.jp/link/ui/2002035722
• 本文言語コード: en
• データソース種別:
  • JaLC
  • Crossref
  • PubMed
  • CiNii Articles
• 抄録ライセンスフラグ: 使用不可